Literature DB >> 16470141

Rate control in atrial fibrillation: looking beyond the average heart rate.

Kamran Ahmad1, Paul Dorian.   

Abstract

PURPOSE OF REVIEW: The aim of this article is to provide a perspective on rate control in atrial fibrillation which emphasizes patient wellbeing (exercise tolerance, symptoms, quality of life) over attempts to reduce resting or exercise heart rate to an arbitrary range. RECENT
FINDINGS: Recent trials of rhythm versus rate control strategies of treatment in patients with atrial fibrillation suggest that rate control is a viable first line strategy in many patients. The adverse consequences of atrial fibrillation with rapid ventricular response are partly due to factors other than rate itself, such as irregularity of ventricular response, and variable changes in autonomic nervous system output. Digoxin, calcium channel blockers, and beta-blockers cause a similar reduction in resting heart rate. Beta blockers are the most potent at reducing exercise heart rate, followed by calcium channel blockers and digoxin. Exercise tolerance is occasionally improved by digoxin, sometimes improved by calcium channel blockers and not improved by (and sometimes decreased by) beta-blockers. Information about quality of life with different rate control regimens is sparse.
SUMMARY: Rate control in atrial fibrillation provides important benefits to patients in terms of symptoms, quality of life and prevention of late consequences of uncontrolled rate (such as tachycardia induced cardiomyopathy). Restricting treatment objectives to achievement of a specific heart rate range on resting or exercise electrocardiogram may result in lack of patient benefit or worsened symptoms. Understanding the nuances of rate control when treating individual patients and interpreting existing evidence allows patients to experience the most benefit from this treatment strategy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16470141     DOI: 10.1097/01.hco.0000210303.33866.c7

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  2 in total

Review 1.  Managing atrial fibrillation.

Authors:  Clare L Atzema; Tyler W Barrett
Journal:  Ann Emerg Med       Date:  2015-02-18       Impact factor: 5.721

2.  Cardiogenic shock induced by bisoprolol in a patient with CYP2D6 variant. A case report.

Authors:  Masafumi Nakayama; Koichi Fuse; Masahito Sato; Masaaki Okabe; Yasushi Komatsu; Akira Yamashina; Yoshifusa Aizawa
Journal:  J Cardiol Cases       Date:  2015-01-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.